Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTIE1VH3)

DOT Name Cellular tumor antigen p53 (TP53)
Synonyms Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53
Gene Name TP53
Related Disease
Breast cancer ( )
Li-Fraumeni syndrome ( )
Obsolete Li-Fraumeni syndrome 1 ( )
Adrenocortical carcinoma, hereditary ( )
Sarcoma ( )
Choroid plexus carcinoma ( )
Bone marrow failure syndrome 5 ( )
UniProt ID
P53_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1A1U ; 1AIE ; 1C26 ; 1DT7 ; 1GZH ; 1H26 ; 1HS5 ; 1JSP ; 1KZY ; 1MA3 ; 1OLG ; 1OLH ; 1PES ; 1PET ; 1SAE ; 1SAF ; 1SAK ; 1SAL ; 1TSR ; 1TUP ; 1UOL ; 1XQH ; 1YC5 ; 1YCQ ; 1YCR ; 1YCS ; 2AC0 ; 2ADY ; 2AHI ; 2ATA ; 2B3G ; 2BIM ; 2BIN ; 2BIO ; 2BIP ; 2BIQ ; 2F1X ; 2FEJ ; 2FOJ ; 2FOO ; 2GS0 ; 2H1L ; 2H2D ; 2H2F ; 2H4F ; 2H4H ; 2H4J ; 2H59 ; 2J0Z ; 2J10 ; 2J11 ; 2J1W ; 2J1X ; 2J1Y ; 2J1Z ; 2J20 ; 2J21 ; 2K8F ; 2L14 ; 2LY4 ; 2MEJ ; 2MWO ; 2MWP ; 2MWY ; 2MZD ; 2OCJ ; 2PCX ; 2RUK ; 2VUK ; 2WGX ; 2X0U ; 2X0V ; 2X0W ; 2XWR ; 2YBG ; 2YDR ; 2Z5S ; 2Z5T ; 3D05 ; 3D06 ; 3D07 ; 3D08 ; 3D09 ; 3D0A ; 3DAB ; 3DAC ; 3IGK ; 3IGL ; 3KMD ; 3KZ8 ; 3LW1 ; 3OQ5 ; 3PDH ; 3Q01 ; 3Q05 ; 3Q06 ; 3SAK ; 3TG5 ; 3TS8 ; 3ZME ; 4AGL ; 4AGM ; 4AGN ; 4AGO ; 4AGP ; 4AGQ ; 4BUZ ; 4BV2 ; 4HFZ ; 4HJE ; 4IBQ ; 4IBS ; 4IBT ; 4IBU ; 4IBV ; 4IBW ; 4IBY ; 4IBZ ; 4IJT ; 4KVP ; 4LO9 ; 4LOE ; 4LOF ; 4MZI ; 4MZR ; 4QO1 ; 4RP6 ; 4RP7 ; 4X34 ; 4XR8 ; 4ZZJ ; 5A7B ; 5AB9 ; 5ABA ; 5AOI ; 5AOJ ; 5AOK ; 5AOL ; 5AOM ; 5BUA ; 5ECG ; 5G4M ; 5G4N ; 5G4O ; 5HOU ; 5HP0 ; 5HPD ; 5LAP ; 5LGY ; 5MCT ; 5MCU ; 5MCV ; 5MCW ; 5MF7 ; 5MG7 ; 5MHC ; 5MOC ; 5O1A ; 5O1B ; 5O1C ; 5O1D ; 5O1E ; 5O1F ; 5O1G ; 5O1H ; 5O1I ; 5OL0 ; 5UN8 ; 5XZC ; 6FF9 ; 6FJ5 ; 6GGA ; 6GGB ; 6GGC ; 6GGD ; 6GGE ; 6GGF ; 6LHD ; 6R5L ; 6RJZ ; 6RK8 ; 6RKI ; 6RKK ; 6RKM ; 6RL3 ; 6RL4 ; 6RL6 ; 6RM5 ; 6RM7 ; 6RWH ; 6RWI ; 6RWS ; 6RWU ; 6RX2 ; 6RZ3 ; 6S39 ; 6S3C ; 6S40 ; 6S9Q ; 6SHZ ; 6SI0 ; 6SI1 ; 6SI2 ; 6SI3 ; 6SI4 ; 6SIN ; 6SIO ; 6SIP ; 6SIQ ; 6SL6 ; 6SLV ; 6T58 ; 6V4F ; 6V4H ; 6VQO ; 6VR1 ; 6VR5 ; 6VRM ; 6VRN ; 6W51 ; 6XRE ; 6ZNC ; 7B46 ; 7B47 ; 7B48 ; 7B49 ; 7B4A ; 7B4B ; 7B4C ; 7B4D ; 7B4E ; 7B4F ; 7B4G ; 7B4H ; 7B4N ; 7BWN ; 7DHY ; 7DHZ ; 7DVD ; 7EAX ; 7EDS ; 7EEU ; 7EL4 ; 7NMI ; 7RM4 ; 7V97 ; 7XZX ; 7XZZ ; 7YGI ; 8A31 ; 8A32 ; 8A92 ; 8DC4 ; 8DC6 ; 8DC7 ; 8DC8 ; 8E7A ; 8E7B ; 8F2H ; 8F2I ; 8HLL ; 8HLM ; 8HLN ; 8OXM ; 8OXO ; 8R1F ; 8R1G ; 8WD2
Pfam ID
PF00870 ; PF08563 ; PF07710 ; PF18521
Sequence
MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGP
DEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAK
SVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHE
RCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNS
SCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELP
PGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPG
GSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD
Function
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. Its pro-apoptotic activity is activated via its interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2. However, this activity is inhibited when the interaction with PPP1R13B/ASPP1 or TP53BP2/ASPP2 is displaced by PPP1R13L/iASPP. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-BMAL1-mediated transcriptional activation of PER2.
Tissue Specificity
Ubiquitous. Isoforms are expressed in a wide range of normal tissues but in a tissue-dependent manner. Isoform 2 is expressed in most normal tissues but is not detected in brain, lung, prostate, muscle, fetal brain, spinal cord and fetal liver. Isoform 3 is expressed in most normal tissues but is not detected in lung, spleen, testis, fetal brain, spinal cord and fetal liver. Isoform 7 is expressed in most normal tissues but is not detected in prostate, uterus, skeletal muscle and breast. Isoform 8 is detected only in colon, bone marrow, testis, fetal brain and intestine. Isoform 9 is expressed in most normal tissues but is not detected in brain, heart, lung, fetal liver, salivary gland, breast or intestine.
KEGG Pathway
Endocrine resistance (hsa01522 )
Platinum drug resistance (hsa01524 )
MAPK sig.ling pathway (hsa04010 )
Sphingolipid sig.ling pathway (hsa04071 )
Cell cycle (hsa04110 )
p53 sig.ling pathway (hsa04115 )
Mitophagy - animal (hsa04137 )
PI3K-Akt sig.ling pathway (hsa04151 )
Apoptosis (hsa04210 )
Longevity regulating pathway (hsa04211 )
Ferroptosis (hsa04216 )
Cellular senescence (hsa04218 )
Wnt sig.ling pathway (hsa04310 )
Neurotrophin sig.ling pathway (hsa04722 )
Thyroid hormone sig.ling pathway (hsa04919 )
Parkinson disease (hsa05012 )
Amyotrophic lateral sclerosis (hsa05014 )
Huntington disease (hsa05016 )
Shigellosis (hsa05131 )
Hepatitis C (hsa05160 )
Hepatitis B (hsa05161 )
Measles (hsa05162 )
Human cytomegalovirus infection (hsa05163 )
Human papillomavirus infection (hsa05165 )
Human T-cell leukemia virus 1 infection (hsa05166 )
Kaposi sarcoma-associated herpesvirus infection (hsa05167 )
Herpes simplex virus 1 infection (hsa05168 )
Epstein-Barr virus infection (hsa05169 )
Pathways in cancer (hsa05200 )
Transcriptio.l misregulation in cancer (hsa05202 )
Viral carcinogenesis (hsa05203 )
Proteoglycans in cancer (hsa05205 )
MicroR.s in cancer (hsa05206 )
Colorectal cancer (hsa05210 )
Pancreatic cancer (hsa05212 )
Endometrial cancer (hsa05213 )
Glioma (hsa05214 )
Prostate cancer (hsa05215 )
Thyroid cancer (hsa05216 )
Basal cell carcinoma (hsa05217 )
Melanoma (hsa05218 )
Bladder cancer (hsa05219 )
Chronic myeloid leukemia (hsa05220 )
Small cell lung cancer (hsa05222 )
Non-small cell lung cancer (hsa05223 )
Breast cancer (hsa05224 )
Hepatocellular carcinoma (hsa05225 )
Gastric cancer (hsa05226 )
Central carbon metabolism in cancer (hsa05230 )
Lipid and atherosclerosis (hsa05417 )
Fluid shear stress and atherosclerosis (hsa05418 )
Reactome Pathway
Activation of PUMA and translocation to mitochondria (R-HSA-139915 )
Pre-NOTCH Transcription and Translation (R-HSA-1912408 )
Oxidative Stress Induced Senescence (R-HSA-2559580 )
Formation of Senescence-Associated Heterochromatin Foci (SAHF) (R-HSA-2559584 )
Oncogene Induced Senescence (R-HSA-2559585 )
DNA Damage/Telomere Stress Induced Senescence (R-HSA-2559586 )
SUMOylation of transcription factors (R-HSA-3232118 )
Autodegradation of the E3 ubiquitin ligase COP1 (R-HSA-349425 )
Association of TriC/CCT with target proteins during biosynthesis (R-HSA-390471 )
Pyroptosis (R-HSA-5620971 )
TP53 Regulates Metabolic Genes (R-HSA-5628897 )
Ub-specific processing proteases (R-HSA-5689880 )
Ovarian tumor domain proteases (R-HSA-5689896 )
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks (R-HSA-5693565 )
Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807 )
TP53 Regulates Transcription of DNA Repair Genes (R-HSA-6796648 )
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release (R-HSA-6803204 )
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain (R-HSA-6803205 )
TP53 Regulates Transcription of Caspase Activators and Caspases (R-HSA-6803207 )
TP53 Regulates Transcription of Death Receptors and Ligands (R-HSA-6803211 )
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest (R-HSA-6804114 )
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain (R-HSA-6804115 )
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest (R-HSA-6804116 )
Regulation of TP53 Expression (R-HSA-6804754 )
Regulation of TP53 Activity through Phosphorylation (R-HSA-6804756 )
Regulation of TP53 Degradation (R-HSA-6804757 )
Regulation of TP53 Activity through Acetylation (R-HSA-6804758 )
Regulation of TP53 Activity through Association with Co-factors (R-HSA-6804759 )
Regulation of TP53 Activity through Methylation (R-HSA-6804760 )
PI5P Regulates TP53 Acetylation (R-HSA-6811555 )
G2/M DNA damage checkpoint (R-HSA-69473 )
G2/M Checkpoints (R-HSA-69481 )
Stabilization of p53 (R-HSA-69541 )
Transcriptional activation of cell cycle inhibitor p21 (R-HSA-69895 )
The role of GTSE1 in G2/M progression after G2 checkpoint (R-HSA-8852276 )
Transcriptional Regulation by VENTX (R-HSA-8853884 )
RUNX3 regulates CDKN1A transcription (R-HSA-8941855 )
Regulation of PTEN gene transcription (R-HSA-8943724 )
Loss of function of TP53 in cancer due to loss of tetramerization ability (R-HSA-9723905 )
Regulation of NF-kappa B signaling (R-HSA-9758274 )
Zygotic genome activation (ZGA) (R-HSA-9819196 )
Factors involved in megakaryocyte development and platelet production (R-HSA-983231 )
PKR-mediated signaling (R-HSA-9833482 )
Activation of NOXA and translocation to mitochondria (R-HSA-111448 )

Molecular Interaction Atlas (MIA) of This DOT

7 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Breast cancer DIS7DPX1 Definitive Autosomal dominant [1]
Li-Fraumeni syndrome DISR64XA Definitive Autosomal dominant [2]
Obsolete Li-Fraumeni syndrome 1 DISNJX6W Definitive Autosomal dominant [1]
Adrenocortical carcinoma, hereditary DIS4PDHI Strong Autosomal dominant [1]
Sarcoma DISZDG3U Strong Autosomal dominant [3]
Choroid plexus carcinoma DISQ04MQ Supportive Autosomal dominant [4]
Bone marrow failure syndrome 5 DISAQK3D Limited Autosomal dominant [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Disease(s)
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
This DOT Affected the Drug Response of 24 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Doxorubicin DMVP5YE Approved Cellular tumor antigen p53 (TP53) decreases the response to substance of Doxorubicin. [91]
Cisplatin DMRHGI9 Approved Cellular tumor antigen p53 (TP53) decreases the response to substance of Cisplatin. [91]
Niclosamide DMJAGXQ Approved Cellular tumor antigen p53 (TP53) increases the response to substance of Niclosamide. [92]
Cytarabine DMZD5QR Approved Cellular tumor antigen p53 (TP53) increases the response to substance of Cytarabine. [93]
Palbociclib DMD7L94 Approved Cellular tumor antigen p53 (TP53) decreases the response to substance of Palbociclib. [94]
Gefitinib DM15F0X Approved Cellular tumor antigen p53 (TP53) affects the response to substance of Gefitinib. [95]
Epanova DMHEAGL Approved Cellular tumor antigen p53 (TP53) affects the response to substance of Epanova. [96]
Zalcitabine DMH7MUV Approved Cellular tumor antigen p53 (TP53) increases the Neoplasm ADR of Zalcitabine. [97]
Pemetrexed DMMX2E6 Approved Cellular tumor antigen p53 (TP53) affects the response to substance of Pemetrexed. [98]
Raltitrexed DMT9K8G Approved Cellular tumor antigen p53 (TP53) affects the response to substance of Raltitrexed. [98]
Didanosine DMI2QPE Approved Cellular tumor antigen p53 (TP53) increases the Neoplasm ADR of Didanosine. [97]
Tegafur DM31ZQM Approved Cellular tumor antigen p53 (TP53) affects the response to substance of Tegafur. [99]
Camptothecin DM6CHNJ Phase 3 Cellular tumor antigen p53 (TP53) decreases the response to substance of Camptothecin. [100]
Rigosertib DMOSTXF Phase 3 Cellular tumor antigen p53 (TP53) affects the response to substance of Rigosertib. [101]
APR-246 DMNFADH Phase 2 Cellular tumor antigen p53 (TP53) affects the response to substance of APR-246. [102]
MK-1775 DM3WDZ5 Phase 2 Cellular tumor antigen p53 (TP53) increases the response to substance of MK-1775. [103]
AMG 232 DM65PTO Phase 2 Cellular tumor antigen p53 (TP53) increases the response to substance of AMG 232. [104]
(+)-JQ1 DM1CZSJ Phase 1 Cellular tumor antigen p53 (TP53) decreases the response to substance of (+)-JQ1. [105]
LMP400 DM4FW2E Phase 1 Cellular tumor antigen p53 (TP53) decreases the response to substance of LMP400. [106]
PMID26882240-Compound-32 DMJS4RP Patented Cellular tumor antigen p53 (TP53) affects the response to substance of PMID26882240-Compound-32. [107]
Nickel chloride DMI12Y8 Investigative Cellular tumor antigen p53 (TP53) decreases the response to substance of Nickel chloride. [108]
Cycloheximide DMGDA3C Investigative Cellular tumor antigen p53 (TP53) increases the response to substance of Cycloheximide. [109]
Dorsomorphin DMKYXJW Investigative Cellular tumor antigen p53 (TP53) increases the response to substance of Dorsomorphin. [110]
CHLORANIL DMCHGF1 Investigative Cellular tumor antigen p53 (TP53) increases the response to substance of CHLORANIL. [111]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 Drug(s)
This DOT Affected the Regulation of Drug Effects of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Adenosine triphosphate DM79F6G Approved Cellular tumor antigen p53 (TP53) increases the abundance of Adenosine triphosphate. [67]
------------------------------------------------------------------------------------
This DOT Affected the Biotransformations of 1 Drug(s)
Drug Name Drug ID Highest Status Interaction REF
Mononitrophenol DM4QO9G Investigative Cellular tumor antigen p53 (TP53) affects the glucuronidation of Mononitrophenol. [112]
------------------------------------------------------------------------------------
9 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of Cellular tumor antigen p53 (TP53). [5]
Arsenic DMTL2Y1 Approved Arsenic decreases the methylation of Cellular tumor antigen p53 (TP53). [11]
Vorinostat DMWMPD4 Approved Vorinostat increases the acetylation of Cellular tumor antigen p53 (TP53). [16]
Panobinostat DM58WKG Approved Panobinostat increases the acetylation of Cellular tumor antigen p53 (TP53). [26]
Aspirin DM672AH Approved Aspirin increases the acetylation of Cellular tumor antigen p53 (TP53). [36]
Etoposide DMNH3PG Approved Etoposide increases the acetylation of Cellular tumor antigen p53 (TP53). [37]
Ursodeoxycholic acid DMCUT21 Approved Ursodeoxycholic acid increases the ubiquitination of Cellular tumor antigen p53 (TP53). [64]
Dihydroartemisinin DMBXVMZ Approved Dihydroartemisinin increases the phosphorylation of Cellular tumor antigen p53 (TP53). [69]
Etretinate DM2CZFA Approved Etretinate increases the phosphorylation of Cellular tumor antigen p53 (TP53). [76]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Drug(s)
89 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Cellular tumor antigen p53 (TP53). [6]
Tretinoin DM49DUI Approved Tretinoin decreases the expression of Cellular tumor antigen p53 (TP53). [7]
Acetaminophen DMUIE76 Approved Acetaminophen decreases the expression of Cellular tumor antigen p53 (TP53). [8]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate decreases the expression of Cellular tumor antigen p53 (TP53). [9]
Estradiol DMUNTE3 Approved Estradiol decreases the expression of Cellular tumor antigen p53 (TP53). [10]
Quercetin DM3NC4M Approved Quercetin increases the expression of Cellular tumor antigen p53 (TP53). [12]
Temozolomide DMKECZD Approved Temozolomide increases the expression of Cellular tumor antigen p53 (TP53). [13]
Arsenic trioxide DM61TA4 Approved Arsenic trioxide decreases the expression of Cellular tumor antigen p53 (TP53). [9]
Hydrogen peroxide DM1NG5W Approved Hydrogen peroxide decreases the expression of Cellular tumor antigen p53 (TP53). [14]
Calcitriol DM8ZVJ7 Approved Calcitriol increases the expression of Cellular tumor antigen p53 (TP53). [15]
Triclosan DMZUR4N Approved Triclosan decreases the expression of Cellular tumor antigen p53 (TP53). [17]
Carbamazepine DMZOLBI Approved Carbamazepine affects the expression of Cellular tumor antigen p53 (TP53). [18]
Methotrexate DM2TEOL Approved Methotrexate decreases the expression of Cellular tumor antigen p53 (TP53). [19]
Decitabine DMQL8XJ Approved Decitabine increases the expression of Cellular tumor antigen p53 (TP53). [20]
Zoledronate DMIXC7G Approved Zoledronate increases the expression of Cellular tumor antigen p53 (TP53). [21]
Selenium DM25CGV Approved Selenium increases the expression of Cellular tumor antigen p53 (TP53). [22]
Progesterone DMUY35B Approved Progesterone increases the expression of Cellular tumor antigen p53 (TP53). [23]
Menadione DMSJDTY Approved Menadione increases the expression of Cellular tumor antigen p53 (TP53). [24]
Fluorouracil DMUM7HZ Approved Fluorouracil decreases the expression of Cellular tumor antigen p53 (TP53). [25]
Fulvestrant DM0YZC6 Approved Fulvestrant decreases the expression of Cellular tumor antigen p53 (TP53). [27]
Dexamethasone DMMWZET Approved Dexamethasone decreases the expression of Cellular tumor antigen p53 (TP53). [28]
Folic acid DMEMBJC Approved Folic acid increases the expression of Cellular tumor antigen p53 (TP53). [29]
Cannabidiol DM0659E Approved Cannabidiol decreases the expression of Cellular tumor antigen p53 (TP53). [30]
Bortezomib DMNO38U Approved Bortezomib increases the activity of Cellular tumor antigen p53 (TP53). [31]
Troglitazone DM3VFPD Approved Troglitazone decreases the expression of Cellular tumor antigen p53 (TP53). [32]
Hydroquinone DM6AVR4 Approved Hydroquinone decreases the expression of Cellular tumor antigen p53 (TP53). [33]
Diethylstilbestrol DMN3UXQ Approved Diethylstilbestrol decreases the expression of Cellular tumor antigen p53 (TP53). [9]
Rosiglitazone DMILWZR Approved Rosiglitazone increases the expression of Cellular tumor antigen p53 (TP53). [34]
Azathioprine DMMZSXQ Approved Azathioprine increases the mutagenesis of Cellular tumor antigen p53 (TP53). [35]
Irinotecan DMP6SC2 Approved Irinotecan increases the expression of Cellular tumor antigen p53 (TP53). [38]
Paclitaxel DMLB81S Approved Paclitaxel increases the expression of Cellular tumor antigen p53 (TP53). [39]
Diclofenac DMPIHLS Approved Diclofenac increases the expression of Cellular tumor antigen p53 (TP53). [40]
Nicotine DMWX5CO Approved Nicotine decreases the expression of Cellular tumor antigen p53 (TP53). [41]
Dasatinib DMJV2EK Approved Dasatinib decreases the expression of Cellular tumor antigen p53 (TP53). [42]
Clozapine DMFC71L Approved Clozapine increases the expression of Cellular tumor antigen p53 (TP53). [43]
DTI-015 DMXZRW0 Approved DTI-015 increases the expression of Cellular tumor antigen p53 (TP53). [44]
Malathion DMXZ84M Approved Malathion increases the expression of Cellular tumor antigen p53 (TP53). [45]
Indomethacin DMSC4A7 Approved Indomethacin increases the expression of Cellular tumor antigen p53 (TP53). [40]
Menthol DMG2KW7 Approved Menthol increases the expression of Cellular tumor antigen p53 (TP53). [46]
Mitomycin DMH0ZJE Approved Mitomycin increases the expression of Cellular tumor antigen p53 (TP53). [47]
Ethinyl estradiol DMODJ40 Approved Ethinyl estradiol affects the activity of Cellular tumor antigen p53 (TP53). [48]
Azacitidine DMTA5OE Approved Azacitidine affects the activity of Cellular tumor antigen p53 (TP53). [48]
Cidofovir DMA13GD Approved Cidofovir increases the expression of Cellular tumor antigen p53 (TP53). [49]
Simvastatin DM30SGU Approved Simvastatin increases the expression of Cellular tumor antigen p53 (TP53). [50]
Topotecan DMP6G8T Approved Topotecan increases the activity of Cellular tumor antigen p53 (TP53). [51]
Gemcitabine DMSE3I7 Approved Gemcitabine increases the expression of Cellular tumor antigen p53 (TP53). [52]
Melphalan DMOLNHF Approved Melphalan affects the activity of Cellular tumor antigen p53 (TP53). [48]
Fenofibrate DMFKXDY Approved Fenofibrate affects the activity of Cellular tumor antigen p53 (TP53). [53]
Mitoxantrone DMM39BF Approved Mitoxantrone affects the activity of Cellular tumor antigen p53 (TP53). [48]
Cyclophosphamide DM4O2Z7 Approved Cyclophosphamide increases the mutagenesis of Cellular tumor antigen p53 (TP53). [54]
Zidovudine DM4KI7O Approved Zidovudine increases the expression of Cellular tumor antigen p53 (TP53). [55]
Ifosfamide DMCT3I8 Approved Ifosfamide affects the activity of Cellular tumor antigen p53 (TP53). [53]
Clodronate DM9Y6X7 Approved Clodronate affects the activity of Cellular tumor antigen p53 (TP53). [53]
Sulindac DM2QHZU Approved Sulindac increases the expression of Cellular tumor antigen p53 (TP53). [56]
Capsaicin DMGMF6V Approved Capsaicin increases the expression of Cellular tumor antigen p53 (TP53). [57]
Ibuprofen DM8VCBE Approved Ibuprofen affects the activity of Cellular tumor antigen p53 (TP53). [53]
Daunorubicin DMQUSBT Approved Daunorubicin increases the expression of Cellular tumor antigen p53 (TP53). [58]
Acetic Acid, Glacial DM4SJ5Y Approved Acetic Acid, Glacial decreases the expression of Cellular tumor antigen p53 (TP53). [59]
Thalidomide DM70BU5 Approved Thalidomide increases the expression of Cellular tumor antigen p53 (TP53). [60]
Bicalutamide DMZMSPF Approved Bicalutamide increases the expression of Cellular tumor antigen p53 (TP53). [61]
Phenytoin DMNOKBV Approved Phenytoin increases the expression of Cellular tumor antigen p53 (TP53). [62]
Hydroxyurea DMOQVU9 Approved Hydroxyurea increases the expression of Cellular tumor antigen p53 (TP53). [63]
Diphenylpyraline DMW4X37 Approved Diphenylpyraline decreases the expression of Cellular tumor antigen p53 (TP53). [65]
Fluoxetine DM3PD2C Approved Fluoxetine increases the expression of Cellular tumor antigen p53 (TP53). [66]
Adefovir dipivoxil DMMAWY1 Approved Adefovir dipivoxil affects the activity of Cellular tumor antigen p53 (TP53). [53]
Imatinib DM7RJXL Approved Imatinib increases the expression of Cellular tumor antigen p53 (TP53). [67]
Ritonavir DMU764S Approved Ritonavir increases the expression of Cellular tumor antigen p53 (TP53). [68]
Dactinomycin DM2YGNW Approved Dactinomycin increases the activity of Cellular tumor antigen p53 (TP53). [70]
Docetaxel DMDI269 Approved Docetaxel increases the expression of Cellular tumor antigen p53 (TP53). [71]
Cholecalciferol DMGU74E Approved Cholecalciferol increases the expression of Cellular tumor antigen p53 (TP53). [72]
Dopamine DMPGUCF Approved Dopamine increases the expression of Cellular tumor antigen p53 (TP53). [73]
Nitric Oxide DM1RBYG Approved Nitric Oxide increases the expression of Cellular tumor antigen p53 (TP53). [74]
Isoproterenol DMK7MEY Approved Isoproterenol decreases the expression of Cellular tumor antigen p53 (TP53). [75]
Lovastatin DM9OZWQ Approved Lovastatin increases the expression of Cellular tumor antigen p53 (TP53). [50]
Ardeparin DMYRX8B Approved Ardeparin decreases the expression of Cellular tumor antigen p53 (TP53). [77]
Olanzapine DMPFN6Y Approved Olanzapine increases the expression of Cellular tumor antigen p53 (TP53). [43]
Propofol DMB4OLE Approved Propofol increases the expression of Cellular tumor antigen p53 (TP53). [78]
Melatonin DMKWFBT Approved Melatonin increases the expression of Cellular tumor antigen p53 (TP53). [15]
Artesunate DMR27C8 Approved Artesunate increases the expression of Cellular tumor antigen p53 (TP53). [79]
Sevoflurane DMC9O43 Approved Sevoflurane increases the expression of Cellular tumor antigen p53 (TP53). [80]
Gentamicin DMKINJO Approved Gentamicin increases the expression of Cellular tumor antigen p53 (TP53). [82]
Morphine DMRMS0L Approved Morphine increases the expression of Cellular tumor antigen p53 (TP53). [83]
Glutathione DMAHMT9 Approved Glutathione increases the expression of Cellular tumor antigen p53 (TP53). [84]
Ximelegatran DMU8ANS Approved Ximelegatran decreases the expression of Cellular tumor antigen p53 (TP53). [86]
Penicillamine DM40EF6 Approved Penicillamine decreases the expression of Cellular tumor antigen p53 (TP53). [87]
Bleomycin DMNER5S Approved Bleomycin increases the expression of Cellular tumor antigen p53 (TP53). [88]
Hesperetin DMKER83 Approved Hesperetin increases the expression of Cellular tumor antigen p53 (TP53). [89]
Clotrimazole DMMFCIH Approved Clotrimazole increases the expression of Cellular tumor antigen p53 (TP53). [90]
Nifedipine DMSVOZT Approved Nifedipine increases the activity of Cellular tumor antigen p53 (TP53). [52]
------------------------------------------------------------------------------------
⏷ Show the Full List of 89 Drug(s)
2 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT
Drug Name Drug ID Highest Status Interaction REF
Warfarin DMJYCVW Approved Warfarin increases the degradation of Cellular tumor antigen p53 (TP53). [81]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Approved Eicosapentaenoic acid/docosa-hexaenoic acid affects the localization of Cellular tumor antigen p53 (TP53). [85]
------------------------------------------------------------------------------------

References

1 Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
2 Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
3 Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2016 Apr 7;374(14):1391. doi: 10.1056/NEJMc1600338.
4 Increased incidence of choroid plexus carcinoma due to the germline TP53 R337H mutation in southern Brazil. PLoS One. 2011 Mar 22;6(3):e18015. doi: 10.1371/journal.pone.0018015.
5 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
6 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
7 Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
8 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
9 Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
10 Growth-promoting effects of low-level butyl benzyl phthalate exposure on human neuroblastoma SH-SY5Y cells. J Appl Toxicol. 2019 Aug;39(8):1181-1191. doi: 10.1002/jat.3803. Epub 2019 Apr 23.
11 [Relationship between the methylation and mutation of p53 gene and endemic arsenism caused by coal-burning]. Zhonghua Yu Fang Yi Xue Za Zhi. 2011 May;45(5):393-8.
12 A flavonoid isolated from Streptomyces sp. (ERINLG-4) induces apoptosis in human lung cancer A549 cells through p53 and cytochrome c release caspase dependant pathway. Chem Biol Interact. 2014 Dec 5;224:24-35. doi: 10.1016/j.cbi.2014.09.019. Epub 2014 Oct 5.
13 Inactivation of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin. J Neurooncol. 2005 Sep;74(2):141-9. doi: 10.1007/s11060-004-6601-3.
14 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
15 Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro?. J Pineal Res. 2002 Mar;32(2):90-6. doi: 10.1034/j.1600-079x.2002.1821.x.
16 Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. Eur J Med Chem. 2009 May;44(5):1900-12.
17 Primary Human Hepatocyte Spheroids as Tools to Study the Hepatotoxic Potential of Non-Pharmaceutical Chemicals. Int J Mol Sci. 2021 Oct 12;22(20):11005. doi: 10.3390/ijms222011005.
18 Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
19 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
20 TP53 promoter methylation in human gliomas. Acta Neuropathol. 2005 Aug;110(2):178-84. doi: 10.1007/s00401-005-1041-5. Epub 2005 Jul 16.
21 Zoledronic acid-induced oxidative damage and endoplasmic reticulum stress-mediated apoptosis in human embryonic kidney (HEK-293) cells. J Biochem Mol Toxicol. 2022 Aug;36(8):e23083. doi: 10.1002/jbt.23083. Epub 2022 May 19.
22 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
23 Progesterone inhibits human endothelial cell proliferation through a p53-dependent pathway. Cell Mol Life Sci. 2008 Nov;65(23):3839-50. doi: 10.1007/s00018-008-8441-3.
24 Growth suppression induced by antitumor drug vitamin K-3 in human hepatoma HepG2 cells is accompanied by downregulation of proliferating cell nuclear antigen expression. Int J Oncol. 1997 May;10(5):1015-9. doi: 10.3892/ijo.10.5.1015.
25 Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer. 2006 May 18;5:20. doi: 10.1186/1476-4598-5-20.
26 SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-B/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis. 2013 May 16;4(5):e635. doi: 10.1038/cddis.2013.159.
27 Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.
28 Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation. Carcinogenesis. 2009 Feb;30(2):348-55. doi: 10.1093/carcin/bgn266. Epub 2008 Nov 26.
29 Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FR/c-SRC/ERK1/2/NFB/TP53 pathway: in vitro and in vivo studies. Sci Rep. 2015 Jun 9;5:11187. doi: 10.1038/srep11187.
30 Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
31 Identification of Compounds That Inhibit Estrogen-Related Receptor Alpha Signaling Using High-Throughput Screening Assays. Molecules. 2019 Feb 27;24(5):841. doi: 10.3390/molecules24050841.
32 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
33 Poly(ADP-ribosyl)ation enhances H-RAS protein stability and causes abnormal cell cycle progression in human TK6 lymphoblastoid cells treated with hydroquinone. Chem Biol Interact. 2015 Aug 5;238:1-8. doi: 10.1016/j.cbi.2015.05.019. Epub 2015 Jun 3.
34 Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr Relat Cancer. 2007 Jun;14(2):305-15. doi: 10.1677/ERC-06-0003.
35 More epidermal p53 patches adjacent to skin carcinomas in renal transplant recipients than in immunocompetent patients: the role of azathioprine. Exp Dermatol. 2008 Apr;17(4):349-55. doi: 10.1111/j.1600-0625.2007.00651.x. Epub 2007 Nov 2.
36 Aspirin inhibits camptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. Int J Oncol. 2009 Mar;34(3):597-608. doi: 10.3892/ijo_00000185.
37 2,3,7,8-tetrachlorodibenzo-p-dioxin counteracts the p53 response to a genotoxicant by upregulating expression of the metastasis marker agr2 in the hepatocarcinoma cell line HepG2. Toxicol Sci. 2010 Jun;115(2):501-12. doi: 10.1093/toxsci/kfq082. Epub 2010 Mar 18.
38 Irinotecan induces senescence and apoptosis in colonic cells in vitro. Toxicol Lett. 2012 Oct 2;214(1):1-8. doi: 10.1016/j.toxlet.2012.08.004. Epub 2012 Aug 14.
39 Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
40 Development of an alternative zebrafish model for drug-induced intestinal toxicity. J Appl Toxicol. 2018 Feb;38(2):259-273. doi: 10.1002/jat.3520. Epub 2017 Oct 13.
41 Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
42 Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med. 2018 Mar;22(3):1614-1626.
43 Clozapine induces oxidative stress and proapoptotic gene expression in neutrophils of schizophrenic patients. J Clin Psychopharmacol. 2005 Oct;25(5):419-26. doi: 10.1097/01.jcp.0000177668.42640.fe.
44 Inactivated MGMT by O6-benzylguanine is associated with prolonged G2/M arrest in cancer cells treated with BCNU. Oncogene. 2005 Mar 24;24(13):2175-83. doi: 10.1038/sj.onc.1208250.
45 Cancer genes induced by malathion and parathion in the presence of estrogen in breast cells. Int J Mol Med. 2008 Feb;21(2):261-8. doi: 10.3892/ijmm.21.2.261.
46 Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
47 Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
48 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
49 Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
50 Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3.
51 Tracking the cell cycle origins for escape from topotecan action by breast cancer cells. Br J Cancer. 2003 Apr 22;88(8):1310-7. doi: 10.1038/sj.bjc.6600889.
52 High-throughput measurement of the Tp53 response to anticancer drugs and random compounds using a stably integrated Tp53-responsive luciferase reporter. Carcinogenesis. 2002 Jun;23(6):949-57. doi: 10.1093/carcin/23.6.949.
53 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
54 p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397-403.
55 Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
56 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
57 Triggering of transient receptor potential vanilloid type 1 (TRPV1) by capsaicin induces Fas/CD95-mediated apoptosis of urothelial cancer cells in an ATM-dependent manner. Carcinogenesis. 2009 Aug;30(8):1320-9. doi: 10.1093/carcin/bgp138. Epub 2009 Jun 5.
58 Daunorubicin-induced variations in gene transcription: commitment to proliferation arrest, senescence and apoptosis. Biochem J. 2003 Jun 15;372(Pt 3):703-11. doi: 10.1042/BJ20021950.
59 Glycidamide and cis-2-butene-1,4-dial (BDA) as potential carcinogens and promoters of liver cancer - An in vitro study. Food Chem Toxicol. 2022 Aug;166:113251. doi: 10.1016/j.fct.2022.113251. Epub 2022 Jun 21.
60 Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. Lipids Health Dis. 2010 Jun 2;9:56. doi: 10.1186/1476-511X-9-56.
61 Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol. 2005 Jan;57(1):83-92.
62 Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci. 2001 Jan;59(1):118-26.
63 Senescence-like changes induced by hydroxyurea in human diploid fibroblasts. Exp Gerontol. 2000 Aug;35(5):553-71. doi: 10.1016/s0531-5565(00)00108-x.
64 Ursodeoxycholic acid modulates the ubiquitin-proteasome degradation pathway of p53. Biochem Biophys Res Commun. 2010 Oct 1;400(4):649-54. doi: 10.1016/j.bbrc.2010.08.121. Epub 2010 Aug 31.
65 Controlled diesel exhaust and allergen coexposure modulates microRNA and gene expression in humans: Effects on inflammatory lung markers. J Allergy Clin Immunol. 2016 Dec;138(6):1690-1700. doi: 10.1016/j.jaci.2016.02.038. Epub 2016 Apr 24.
66 Fluoxetine inhibits the extracellular signal regulated kinase pathway and suppresses growth of cancer cells. Cancer Biol Ther. 2008 Oct;7(10):1685-93. doi: 10.4161/cbt.7.10.6664. Epub 2008 Oct 22.
67 AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells. Cancer Sci. 2021 Jan;112(1):194-204. doi: 10.1111/cas.14698. Epub 2020 Nov 16.
68 Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer. 2009 Apr 22;8:26. doi: 10.1186/1476-4598-8-26.
69 The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest New Drugs. 2012 Aug;30(4):1289-301. doi: 10.1007/s10637-011-9676-7. Epub 2011 May 6.
70 The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1. Carcinogenesis. 2003 Oct;24(10):1601-14. doi: 10.1093/carcin/bgg116. Epub 2003 Jul 17.
71 Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. Int J Cancer. 2006 Jan 15;118(2):317-25. doi: 10.1002/ijc.21372.
72 Vitamin D ameliorates diethylnitrosamine-induced liver preneoplasia: A pivotal role of CYP3A4/CYP2E1 via DPP-4 enzyme inhibition. Toxicol Appl Pharmacol. 2023 Jan 1;458:116324. doi: 10.1016/j.taap.2022.116324. Epub 2022 Nov 25.
73 Effects of dopamine on LC3-II activation as a marker of autophagy in a neuroblastoma cell model. Neurotoxicology. 2009 Jul;30(4):658-65. doi: 10.1016/j.neuro.2009.04.007. Epub 2009 May 4.
74 Nitric oxide induces oral squamous cell carcinoma cells apoptosis with p53 accumulation. Oral Oncol. 2005 Sep;41(8):785-90. doi: 10.1016/j.oraloncology.2005.04.002.
75 Isoproterenol effects evaluated in heart slices of human and rat in comparison to rat heart in vivo. Toxicol Appl Pharmacol. 2014 Jan 15;274(2):302-12.
76 Synthesis and structure-activity relationships of new antiproliferative and proapoptotic retinoid-related biphenyl-4-yl-acrylic acids. Bioorg Med Chem. 2007 Jul 15;15(14):4863-75. doi: 10.1016/j.bmc.2007.04.057. Epub 2007 May 3.
77 Antitumor effect of butanoylated heparin with low anticoagulant activity on lung cancer growth in mice and rats. Curr Cancer Drug Targets. 2010 Mar;10(2):229-41. doi: 10.2174/156800910791054176.
78 Evaluation of cytotoxicity of propofol and its related mechanism in glioblastoma cells and astrocytes. Environ Toxicol. 2017 Dec;32(12):2440-2454.
79 AMG900 as novel inhibitor of the translationally controlled tumor protein. Chem Biol Interact. 2021 Jan 25;334:109349. doi: 10.1016/j.cbi.2020.109349. Epub 2020 Nov 28.
80 Different apoptosis ratios and gene expressions in two human cell lines after sevoflurane anaesthesia. Acta Anaesthesiol Scand. 2009 Oct;53(9):1192-9. doi: 10.1111/j.1399-6576.2009.02036.x. Epub 2009 Jun 30.
81 P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1. Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15065-70. doi: 10.1073/pnas.2436329100. Epub 2003 Nov 21.
82 In vitro evaluation of biomarkers of nephrotoxicity through gene expression using gentamicin. J Biochem Mol Toxicol. 2018 Sep;32(9):e22189. doi: 10.1002/jbt.22189. Epub 2018 Jul 10.
83 Morphine induces DNA damage and P53 activation in CD3+ T cells. Biochim Biophys Acta. 2009 Aug;1790(8):793-9. doi: 10.1016/j.bbagen.2009.04.011. Epub 2009 May 3.
84 Apoptosis induced by extracellular glutathione is mediated by H(2)O(2) production and DNA damage. Int J Cancer. 2000 Aug 1;87(3):343-8. doi: 10.1002/1097-0215(20000801)87:3<343::aid-ijc6>3.0.co;2-8.
85 Docosahexaenoic acid increases the expression of oxidative stress-induced growth inhibitor 1 through the PI3K/Akt/Nrf2 signaling pathway in breast cancer cells. Food Chem Toxicol. 2017 Oct;108(Pt A):276-288. doi: 10.1016/j.fct.2017.08.010. Epub 2017 Aug 12.
86 Pharmacological inhibition of Rho-kinase (ROCK) signaling enhances cisplatin resistance in neuroblastoma cells. Int J Oncol. 2010 Nov;37(5):1297-305. doi: 10.3892/ijo_00000781.
87 D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
88 Synergistic anticancer activity of dietary tea polyphenols and bleomycin hydrochloride in human cervical cancer cell: Caspase-dependent and independent apoptotic pathways. Chem Biol Interact. 2016 Mar 5;247:1-10. doi: 10.1016/j.cbi.2016.01.012. Epub 2016 Jan 29.
89 Various concentrations of hesperetin induce different types of programmed cell death in human breast cancerous and normal cell lines in a ROS-dependent manner. Chem Biol Interact. 2023 Sep 1;382:110642. doi: 10.1016/j.cbi.2023.110642. Epub 2023 Jul 23.
90 Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. J Neurosurg. 1999 May;90(5):918-27. doi: 10.3171/jns.1999.90.5.0918.
91 p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
92 Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
93 Chromosome breakage induced by the genotoxic agents mitomycin C and cytosine arabinoside is concentration and p53 dependent. Toxicol Sci. 2014 Jul;140(1):94-102. doi: 10.1093/toxsci/kfu058. Epub 2014 Mar 27.
94 Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 2011 Mar 15;17(6):1591-602. doi: 10.1158/1078-0432.CCR-10-2307. Epub 2011 Jan 28.
95 Aurora-A promotes gefitinib resistance via a NF-B signaling pathway in p53 knockdown lung cancer cells. Biochem Biophys Res Commun. 2011 Feb 11;405(2):168-72. doi: 10.1016/j.bbrc.2011.01.001. Epub 2011 Jan 7.
96 The effects of Omega-3 fatty acids on growth regulation of epithelial ovarian cancer cell lines. Gynecol Oncol. 2005 Oct;99(1):58-64. doi: 10.1016/j.ygyno.2005.05.024.
97 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
98 Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer. 2007 Mar 12;96(5):769-75.
99 Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. Cancer Sci. 2004 Jun;95(6):541-6. doi: 10.1111/j.1349-7006.2004.tb03246.x.
100 SIRT1 inhibition restores apoptotic sensitivity in p53-mutated human keratinocytes. Toxicol Appl Pharmacol. 2014 Jun 15;277(3):288-97. doi: 10.1016/j.taap.2014.04.001. Epub 2014 Apr 12.
101 The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther. 2013 Oct;12(10):1994-2005. doi: 10.1158/1535-7163.MCT-13-0206. Epub 2013 Jul 19.
102 Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene. 2010 Mar 4;29(9):1329-38. doi: 10.1038/onc.2009.425. Epub 2009 Nov 30.
103 Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.
104 Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells. Cell Death Dis. 2018 Jul 18;9(8):792. doi: 10.1038/s41419-018-0825-1.
105 BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget. 2013 Nov;4(11):2080-95.
106 ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses. Cancer Res. 2014 Dec 1;74(23):6968-79.
107 Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines. Clin Cancer Res. 2006 Nov 1;12(21):6547-56. doi: 10.1158/1078-0432.CCR-06-1178.
108 p53 activation by Ni(II) is a HIF-1 independent response causing caspases 9/3-mediated apoptosis in human lung cells. Toxicol Appl Pharmacol. 2013 Jun 15;269(3):233-9. doi: 10.1016/j.taap.2013.03.023. Epub 2013 Apr 6.
109 Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage. Mol Pharmacol. 2011 Dec;80(6):1000-12. doi: 10.1124/mol.111.074708. Epub 2011 Aug 29.
110 p53 modulates the AMPK inhibitor compound C induced apoptosis in human skin cancer cells. Toxicol Appl Pharmacol. 2013 Feb 15;267(1):113-24. doi: 10.1016/j.taap.2012.12.016. Epub 2012 Dec 27.
111 Unpredicted Downregulation of RAD51 Suggests Genome Instability Induced by Tetrachlorobenzoquinone. Chem Res Toxicol. 2016 Dec 19;29(12):2184-2193. doi: 10.1021/acs.chemrestox.6b00369. Epub 2016 Nov 21.
112 Comparison of the levels of enzymes involved in drug metabolism between transgenic or gene-knockout and the parental mice. Toxicol Pathol. 2001;29 Suppl:161-72. doi: 10.1080/019262301753178573.